Mast Therapeutics, Inc. (MSTX)

[Blinkx90]

My comment to the SA piece:
Unfortunately you missed the most important piece of the Mast story, you did not do an evaluation of the redesigned phase 3 trial, EPIC, which is currently 70%+ enrolled.


http://bit.ly/19F8Yo4


If you don't have a basic understanding of statistics and are involved with MSTX, I would "hire" a grad student, give him the above link, tell him that the average age of those enrolled in EPIC will probably end up around 17 and that those on concurrent Hydroxyurea + MST-118 will probably be around 30%. Have him explain to you how HIGH the probability of EPIC hitting statistical significance is. A new phase 3 trial design based on a prior failed trial's subset analysis is one of the best set ups EVER for a biotech investor, see ACAD , $1.25 to $40.


BlinkX90